Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes

Sophie Paczesny, Jochen Metzger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy. The past decade has been characterized by an explosive evolution of proteomics technologies, largely due to important advances in high-throughput MS instruments and bioinformatics. Building on these opportunities, blood biomarkers have been identified and validated both as promising diagnostic tools, prognostic tools that risk-stratify patients before future occurrence of GVHD and as predictive tools for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers might facilitate timely and selective therapeutic intervention. This review summarizes current information on clinical proteomics for GVHD as well as other complications following HSCT. Finally, it proposes future directions for the translation of clinical proteomics to discovery of new potential therapeutic targets to the development of drugs.

Original languageEnglish (US)
Article number1800145
JournalProteomics - Clinical Applications
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Stem Cell Transplantation
Stem cells
Grafts
Proteomics
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Biomarkers
Leukemia
Transplants
Therapeutics
Mortality
Computational Biology
Immunotherapy
Disease Progression
Bioinformatics
Tumors
Technology
Morbidity
Blood
Throughput

Keywords

  • biomarkers
  • graft-versus-host disease
  • Hematopoetic cell transplantation
  • Proteomics
  • validation

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes. / Paczesny, Sophie; Metzger, Jochen.

In: Proteomics - Clinical Applications, 01.01.2018.

Research output: Contribution to journalArticle

@article{32de2118ae644a8689372805bc3c04f2,
title = "Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy. The past decade has been characterized by an explosive evolution of proteomics technologies, largely due to important advances in high-throughput MS instruments and bioinformatics. Building on these opportunities, blood biomarkers have been identified and validated both as promising diagnostic tools, prognostic tools that risk-stratify patients before future occurrence of GVHD and as predictive tools for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers might facilitate timely and selective therapeutic intervention. This review summarizes current information on clinical proteomics for GVHD as well as other complications following HSCT. Finally, it proposes future directions for the translation of clinical proteomics to discovery of new potential therapeutic targets to the development of drugs.",
keywords = "biomarkers, graft-versus-host disease, Hematopoetic cell transplantation, Proteomics, validation",
author = "Sophie Paczesny and Jochen Metzger",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/prca.201800145",
language = "English (US)",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes

AU - Paczesny, Sophie

AU - Metzger, Jochen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy. The past decade has been characterized by an explosive evolution of proteomics technologies, largely due to important advances in high-throughput MS instruments and bioinformatics. Building on these opportunities, blood biomarkers have been identified and validated both as promising diagnostic tools, prognostic tools that risk-stratify patients before future occurrence of GVHD and as predictive tools for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers might facilitate timely and selective therapeutic intervention. This review summarizes current information on clinical proteomics for GVHD as well as other complications following HSCT. Finally, it proposes future directions for the translation of clinical proteomics to discovery of new potential therapeutic targets to the development of drugs.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy. The past decade has been characterized by an explosive evolution of proteomics technologies, largely due to important advances in high-throughput MS instruments and bioinformatics. Building on these opportunities, blood biomarkers have been identified and validated both as promising diagnostic tools, prognostic tools that risk-stratify patients before future occurrence of GVHD and as predictive tools for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers might facilitate timely and selective therapeutic intervention. This review summarizes current information on clinical proteomics for GVHD as well as other complications following HSCT. Finally, it proposes future directions for the translation of clinical proteomics to discovery of new potential therapeutic targets to the development of drugs.

KW - biomarkers

KW - graft-versus-host disease

KW - Hematopoetic cell transplantation

KW - Proteomics

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85055097455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055097455&partnerID=8YFLogxK

U2 - 10.1002/prca.201800145

DO - 10.1002/prca.201800145

M3 - Article

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

M1 - 1800145

ER -